Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia is the lead sponsor of 13 current clinical trials in our Italy, Germany, Spain, Netherlands, Belgium and EU (CTIS) registers. 7 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Cemiplimab, Cisplatin and Doravirine. The most-studied condition is Corneal Transplant Failure.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Bio-CAR-T BS Study
NCT05366569 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Acute Lymphoblastic Leukemia (ALL)
|
Observational | Recruiting | 2022-04 | Italy |
|
The Viability Control of Human Endothelial Cells Before Keratoplasty (V-CHECK) Study
NCT05847387 · ClinicalTrials.gov ↗ · Corneal Transplant Failure, Corneal Endothelial Cell Loss
|
Observational | Recruiting | 2023-12 | Germany, Spain, Italy, Netherlands, Belgium |
|
Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)
NCT05913427 · ClinicalTrials.gov ↗ · Adrenocortical Carcinoma
Drug: Megestrol Acetate |
Phase 2 | Recruiting | 2022-06 | Italy |
|
Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer
NCT07085572 · ClinicalTrials.gov ↗ · Adrenal Cortical Carcinoma
Drug: Cemiplimab |
Phase 2 | Recruiting | 2025-09 | Italy |
|
Effectiveness of EMDR in Borderline Personality Disorder
NCT06493708 · ClinicalTrials.gov ↗ · Borderline Personality Disorder
|
Not applicable | Recruiting | 2024-10 | Italy |
|
Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes
NCT03058588 · ClinicalTrials.gov ↗ · Leukemia
|
Observational | Recruiting | 2017-02 | Italy |
|
Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial
NCT07420790 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia
|
Observational | Recruiting | 2026-02 | Italy |
|
Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia
NCT07232953 · ClinicalTrials.gov ↗ · Acute Myeloid Leukaemia (AML), Hematopoietic Stem Cell Transplant (HSCT)
Drugs: Fludarabine, Treosulfan |
Phase 2 | Active, closed | 2022-11 | Italy |
|
Fitness in Elderly AML Patients
NCT07598838 · ClinicalTrials.gov ↗ · AML (Acute Myelogenous Leukemia
|
Observational | Active, closed | 2020-01 | Italy |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
Hyperthermic Intraperitoneal Chemotherapy and Regional Adrenalectomy in the management of Stage II & III Adrenocortical Carcinoma
2026-525406-36-00 · Neoplasms
Drugs: Cisplatin, Doxorubicin |
Phase 2 | Authorised | Italy |
|
Valproic acid and lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma
2026-525733-24-00 · Neoplasms
Drugs: Lenvatinib, Sodium valproate |
Phase 2 | Authorised | Italy |
|
Efficacy of cell therapy with allo-MSCs in patients with gvhd resistant to ruxolitinib second line therapy: a Phase IIB Clinical Trial - MSC-GRR2 Study
2025-523448-10-00 · CTIS ↗ · Hemic and Lymphatic Diseases
Drug: MC0518 |
Phase 2 | Authorised | Italy |
|
Randomized Multicentric Proof-of-Concept Phase 2 Trial Doravirine in the Early Outpatient Management of
West Nile Virus Infection in Patients at Risk of Progression - DORICO Trial
2025-521677-14-00 · CTIS ↗ · Virus Diseases
Drug: Doravirine |
Phase 2 | Authorised | Italy |
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Italy | 9 | 7 |
| Clinical trials in Germany | 1 | 1 |
| Clinical trials in Spain | 1 | 1 |
| Clinical trials in Netherlands | 1 | 1 |
| Clinical trials in Belgium | 1 | 1 |
| EU register (CTIS) | 4 | — |
A trial with sites in more than one country appears in each of those registers.
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia is the lead sponsor of 9 current trials on ClinicalTrials.gov in our Italy, Germany, Spain, Netherlands and Belgium registers, and 4 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 7 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 10 drugs and biologicals as interventions. The most frequent are Cemiplimab (1), Cisplatin (1), Doravirine (1), Doxorubicin (1) and Fludarabine (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.